220 related articles for article (PubMed ID: 31833658)
1. Metabolic imaging using hyperpolarized
Acciardo S; Mignion L; Lacomblez E; Schoonjans C; Joudiou N; Gourgue F; Bouzin C; Baurain JF; Gallez B; Jordan BF
J Cell Mol Med; 2020 Jan; 24(2):1934-1944. PubMed ID: 31833658
[TBL] [Abstract][Full Text] [Related]
2. Multi-sample measurement of hyperpolarized pyruvate-to-lactate flux in melanoma cells.
Lees H; Millan M; Ahamed F; Eskandari R; Granlund KL; Jeong S; Keshari KR
NMR Biomed; 2021 Mar; 34(3):e4447. PubMed ID: 33314422
[TBL] [Abstract][Full Text] [Related]
3. The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.
Delgado-Goni T; Miniotis MF; Wantuch S; Parkes HG; Marais R; Workman P; Leach MO; Beloueche-Babari M
Mol Cancer Ther; 2016 Dec; 15(12):2987-2999. PubMed ID: 27765851
[TBL] [Abstract][Full Text] [Related]
4. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
5. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Misek SA; Newbury PA; Chekalin E; Paithankar S; Doseff AI; Chen B; Gallo KA; Neubig RR
Mol Pharmacol; 2022 Jan; 101(1):1-12. PubMed ID: 34732527
[TBL] [Abstract][Full Text] [Related]
7. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf
Wu PK; Hong SK; Park JI
Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231
[TBL] [Abstract][Full Text] [Related]
8. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
Babagana M; Johnson S; Slabodkin H; Bshara W; Morrison C; Kandel ES
Mol Carcinog; 2017 May; 56(5):1515-1525. PubMed ID: 28052407
[TBL] [Abstract][Full Text] [Related]
9. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
Zuo Q; Liu J; Huang L; Qin Y; Hawley T; Seo C; Merlino G; Yu Y
Oncogene; 2018 Jun; 37(24):3275-3289. PubMed ID: 29551771
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
11. Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
Delgado-Goñi T; Galobart TC; Wantuch S; Normantaite D; Leach MO; Whittaker SR; Beloueche-Babari M
Br J Cancer; 2020 Jan; 122(1):72-81. PubMed ID: 31819183
[TBL] [Abstract][Full Text] [Related]
12. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
13. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
Atay C; Kwak T; Lavilla-Alonso S; Donthireddy L; Richards A; Moberg V; Pilon-Thomas S; Schell M; Messina JL; Rebecca VW; Xiao M; Tan J; Zhang G; Weber JS; Herlyn M; Sarnaik AA; Gabrilovich DI
Clin Cancer Res; 2019 May; 25(9):2783-2794. PubMed ID: 30765391
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
15. LncRNA SAMMSON Mediates Adaptive Resistance to RAF Inhibition in BRAF-Mutant Melanoma Cells.
Han S; Yan Y; Ren Y; Hu Y; Wang Y; Chen L; Zhi Z; Zheng Y; Shao Y; Liu J
Cancer Res; 2021 Jun; 81(11):2918-2929. PubMed ID: 34087780
[TBL] [Abstract][Full Text] [Related]
16. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
18. Development and in-depth characterization of BRAFi-resistant melanoma cell lines in vitro and in vivo.
Saraswat A; Patel K
Exp Cell Res; 2024 May; 438(1):114033. PubMed ID: 38593916
[TBL] [Abstract][Full Text] [Related]
19. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.
Parmenter TJ; Kleinschmidt M; Kinross KM; Bond ST; Li J; Kaadige MR; Rao A; Sheppard KE; Hugo W; Pupo GM; Pearson RB; McGee SL; Long GV; Scolyer RA; Rizos H; Lo RS; Cullinane C; Ayer DE; Ribas A; Johnstone RW; Hicks RJ; McArthur GA
Cancer Discov; 2014 Apr; 4(4):423-33. PubMed ID: 24469106
[TBL] [Abstract][Full Text] [Related]
20. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
